XML 44 R34.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Acquisitions of Assets - Additional Information (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Dec. 31, 2023 USD ($) shares | Nov. 30, 2023 USD ($) | Feb. 28, 2022 USD ($) | Sep. 30, 2021 USD ($) Agreements shares | Nov. 30, 2020 USD ($) | Sep. 30, 2020 USD ($) | Jun. 30, 2020 USD ($) | Mar. 31, 2024 USD ($) Milestones | Dec. 31, 2023 USD ($) | Dec. 31, 2023 USD ($)
Amgen Inc. |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Number of license agreements | Agreements |  |  |  | 2 |  |  |  |  |  |
Vanderbilt IPR&D Assets |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration deemed due or payable |  |  |  |  |  |  |  | $ 0 |  |
BlackThorn Merger Agreement |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration, milestone payment settled in cash |  |  |  |  |  |  | $ 10,000,000 |  |  |
Number of milestone achieved | Milestones |  |  |  |  |  |  |  | 0 |  |
BlackThorn Merger Agreement | BlackThorn Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration deemed due or payable |  |  |  |  |  |  |  | $ 0 |  |
Contingent consideration payable in cash | $ 2,300,000 |  |  |  |  |  |  |  |  |
Acquired in-process research and developed expense |  |  |  |  |  |  |  |  | $ 60,800,000 |
BlackThorn Merger Agreement | BlackThorn Therapeutics, Inc. | Common Stock |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Shares issued based on volume weighted average price per share prior to date milestone was met | shares | 6,072,445 |  |  |  |  |  |  |  |  |
BlackThorn Merger Agreement | navacaprant |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Milestone payment due description |  |  |  |  |  |  |  | milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant, |  |
BlackThorn Merger Agreement | navacaprant | Maximum | Development and Regulatory Approval Milestones |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  | 365,000,000 |  |  |
BlackThorn Merger Agreement | navacaprant | Maximum | Sales-based Milestones |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  | 450,000,000 |  |  |
BlackThorn Merger Agreement | NMRA-511 | Maximum | Development and Regulatory Approval Milestones |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  | 100,000,000 |  |  |
BlackThorn Merger Agreement | NMRA-511 | Maximum | Sales-based Milestones |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  | $ 100,000,000 |  |  |
BlackThorn Carveout Plan |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Number of milestone achieved | Milestones |  |  |  |  |  |  |  | 0 |  |
Contingent consideration deemed due or payable |  |  |  |  |  |  |  | $ 0 |  |
Asset acquisition compensation recognized and paid |  |  |  |  |  |  |  |  |  | $ 1,800,000
Syllable Merger Agreement | Syllable Life Sciences, Inc |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Number of milestone achieved | Milestones |  |  |  |  |  |  |  | 0 |  |
Contingent consideration deemed due or payable |  |  |  |  |  |  |  | $ 0 |  |
Syllable Merger Agreement | Syllable Life Sciences, Inc | Maximum | Development Milestones |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  | $ 5,000,000 |  |  |  |
Alairion Merger Agreement | Alairion, Inc |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Number of milestone achieved | Milestones |  |  |  |  |  |  |  | 0 |  |
Alairion Merger Agreement | Alairion, Inc | Achievement of Specified Commercialization Events |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration, milestone payment |  |  |  |  | $ 135,000,000 |  |  |  |  |
Alairion Merger Agreement | Alairion, Inc | Maximum | Achievement of Specified Development Events |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration, milestone payment |  |  |  |  | $ 33,500,000 |  |  |  |  |
Amgen Inc. Licenses | Amgen Inc. |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Number of milestone achieved | Milestones |  |  |  |  |  |  |  | 0 |  |
Contingent consideration deemed due or payable |  |  |  |  |  |  |  | $ 0 |  |
Amgen Inc. Licenses | Amgen Inc. | Series A-2 |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront consideration transferred shares | shares |  |  |  | 20,000,000 |  |  |  |  |  |
Acquisition date fair value of shares transferred |  |  |  | $ 157,000,000 |  |  |  |  |  |
Amgen Inc. Licenses | Amgen Inc. | Maximum | Case One |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration payable in cash |  |  |  | 360,000,000 |  |  |  |  |  |
Amgen Inc. Licenses | Amgen Inc. | Maximum | Commercial Milestone Payment | Case Two |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration payable in cash |  |  |  | $ 360,000,000 |  |  |  |  |  |
Vanderbilt License |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration, milestone payment settled in cash |  | $ 2,000,000 |  |  |  |  |  |  |  |
Number of milestone achieved | Milestones |  |  |  |  |  |  |  | 0 |  |
Acquired in-process research and development |  |  |  |  |  |  |  |  | $ 800,000 |
Vanderbilt License | Maximum | Achievement of Specified Development Events |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration payable in cash |  |  | $ 42,400,000 |  |  |  |  |  |  |
Vanderbilt License | Maximum | Achievement of Specified Commercialization Events |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Contingent consideration payable in cash |  |  | 380,000,000 |  |  |  |  |  |  |
Vanderbilt License | Vanderbilt IPR&D Assets |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront cash payment |  |  | $ 13,000,000 |  |  |  |  |  |  |

X
- Definition Acquired in-process research and developed expense. + References No definition available. + Details
Name: | nmra_AcquiredInProcessResearchAndDevelopedExpense
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Acquired in-process research and development + References No definition available. + Details
Name: | nmra_AcquiredInProcessResearchAndDevelopment
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Acquisition date fair value of shares transferred + References No definition available. + Details
Name: | nmra_AcquisitionDateFairValueOfSharesTransferred
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent consideration, milestone payment. + References No definition available. + Details
Name: | nmra_ContingentConsiderationMilestonePayment
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent consideration, milestone payment settled in cash + References No definition available. + Details
Name: | nmra_ContingentConsiderationMilestonePaymentSettledInCash
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment due description. + References No definition available. + Details
Name: | nmra_MilestonePaymentDueDescription
Namespace Prefix: | nmra_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of license agreements. + References No definition available. + Details
Name: | nmra_NumberOfLicenseAgreements
Namespace Prefix: | nmra_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of milestone achieved. + References No definition available. + Details
Name: | nmra_NumberOfMilestoneAchieved
Namespace Prefix: | nmra_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Shares issued based on volume weighted average price per share prior to date milestone was met. + References No definition available. + Details
Name: | nmra_SharesIssuedBasedOnVolumeWeightedAveragePricePerSharePriorToDateMilestoneWasMet
Namespace Prefix: | nmra_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | nmra_UpfrontCashPayment
Namespace Prefix: | nmra_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront consideration transferred shares. + References No definition available. + Details
Name: | nmra_UpfrontConsiderationTransferredShares
Namespace Prefix: | nmra_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of contingent consideration recognized as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized from contingent consideration in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=nmra_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=nmra_VanderbiltIprDAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_BlackthornMergerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=nmra_BlackthornTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=nmra_NavacaprantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentAndRegulatoryApprovalMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=nmra_SalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=nmra_Nmra511Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_BlackthornCarveoutPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_SyllableMergerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=nmra_SyllableLifeSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=nmra_DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_AlairionMergerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=nmra_AlairionIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedCommercializationEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=nmra_AchievementOfSpecifiedDevelopmentEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_AmgenIncLicensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=nmra_SeriesA2ConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=nmra_CaseOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=nmra_CommercialMilestonePaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=nmra_CaseTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nmra_VanderbiltLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |